Affordable Access

Publisher Website

Imported Chikungunya Infection, Italy

Centers for Disease Control and Prevention
Publication Date
DOI: 10.3201/eid1308.070161
  • Letters To The Editor
  • Medicine


Letters.indd LETTERS 1264 Emerging Infectious Diseases • • Vol. 13, No. 8, August 2007 8. Gerber A, Karch H, Allerberger F, Ver- weyen HM, Zimmerhackl LB. Clinical course and the role of Shiga toxin–pro- ducing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997–2000, in Germany and Austria: a prospective study. J Infect Dis. 2002;186:493–500. 9. Ethelberg S, Olsen KE, Scheutz F, Jen- sen C, Schiellerup P, Engberg J, et al. Virulence factors for hemolytic uremic syndrome, Denmark. Emerg Infect Dis. 2004;5:842–7. 10. Centers for Disease Control and Preven- tion. Summary of notifi able diseases, United States. [cited 2007 Jan 11]. Avail- able from summary.html Address for correspondence: Vivian Marie Lockary, Idaho Bureau of Laboratories, 2220 Old Penitentiary Rd, Boise, ID 83712, USA; email: [email protected] Imported Chikungunya Infection, Italy To the Editor: Chikungunya vi- rus (CHIKV) infection is a self-lim- iting illness characterized by fever, headache, weakness, rash, and arthral- gia. Some patients have prolonged weakness or arthralgia lasting several months. In 2006, several Indian Ocean states and India had an outbreak of CHIKV infection (1,2). During the epidemic’s peak, some European and American travelers returning from these areas were infected (3–6). Because the foci of Aedes al- bopictus, 1 of the 2 main vectors of CHIKV, are now in Italy and many travelers visit CHIKV-epidemic ar- eas, surveillance for imported cases is mandatory in Italy (7). From July to September 2006, a total of 17 con- fi rmed cases of CHIKV infection were observed in travelers at 5 Gruppo di Interesse e Studio delle Patologie di Importazione (GISPI) centers (Italian network of Institutes of Infectious and Tropical Diseases). Serologic diagno- sis was performed with a hemagglu- tination-inhibition test and confi rmed by a plaque-reduction neutralization test (

There are no comments yet on this publication. Be the first to share your thoughts.


Seen <100 times